Amryt Pharma PLC Fundamentals Datasheet and Stock Analysis

Profile

Amryt Pharma PLC Company Logo
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. The Company holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body’s ability to remove LDL cholesterol (bad cholesterol) from the blood.

  • Current Price:
     14.50p
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
     GB00BDD1LS57
  • Market Sector:
     AIM
  • Main Indices:
     FTSE AIM
  • Country of register:
     Great Britain
  • Currency:
     N/A
  • Shares in Issue:
     275m
  • Market Cap:
     £1m
  • Date Listed:
     19/04/2016
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)

Loading...

Activity Data Not Available

Company Information

CEO: Joe Wiley  CFO: Rory Nealon  Non-Executive Director: Ray Stafford, Markus Ziener James Culverwell  Non-Executive Chairman: Harry Stratford  

  • Registrars:
     
  • Address:
     Dept 920A, 196, High Road, Wood Green, London, United Kingdom
  • Phone:
     
  • Website:
     
Analysis
Composite Ranking: 24
Historic EPS Ranking: 37
Forecast EPS Ranking: 19
Price Relative Strength: 30
Industry Strength: I
SMR Ranking: D
ROCE Ranking: A
Accumulation/Dist: 
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: H
Chart
Add Indicator




loading




Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Fundamentals
2013201420152015201620172018E2019E
Day/Month31/331/331/331/1231/1231/1231/1231/12
Revenue€m0.000.000.000.001.3512.78$m13.9717.70
Operating Profit/(loss)€m(3.51)(2.93)(2.04)(0.55)(7.68)(14.21)$m0.000.00
Profit Before Tax€m(2.12)(2.56)(1.87)(1.19)(7.80)(26.14)$m(21.23)(25.91)
Profit After Tax€m(2.12)(2.56)(1.87)(1.19)(7.80)(26.14)$m0.000.00
Profit After Tax (from discontinued operations)€m0.000.00(34.10)0.000.000.00$m0.000.00
Overall Profit for the Period€m(2.12)(2.56)(35.97)(1.19)(7.80)(26.14)$m0.000.00
EPS Growth%0.000.000.000.000.000.00%0.000.00
Earnings Per Share¢(1.09)(0.87)(4.32)(2.84)(4.78)(11.72)p(8.65)(8.24)
Op. Cash Flow P/S¢(0.04)(0.04)(0.08)(1.63)(0.04)(0.05)$0.000.00
Cash Flow P/S Grth%0.000.000.000.000.000.00%0.000.00
Net Cash Flow P/S¢0.000.000.000.000.000.00$0.000.00
Capital Exp P/S0.000.000.000.000.000.00$0.000.00
Tax Rate%0.000.000.000.000.000.00%0.000.00
P/E Ratiox0.000.000.000.000.000.00x0.000.00
P/E Growth0.000.000.000.000.000.00$0.000.00
Turnover Per Share0.000.000.000.000.000.00$0.000.00
Pre-Tax Profit / Share0.000.000.000.000.000.00$0.000.00
Operating Margin%0.000.000.000.00(568.89)(111.19)%0.000.00
ROCE%(4.32)(5.24)(13.71)(11.98)(12.64)(35.98)%0.000.00
ROE%(9.67)(5.02)(129.43)(76.30)(23.62)(95.17)%0.000.00
Mkt Cap€m70.7729.205.777.2853.5955.31$m0.000.00
Dividend Per Share¢0.000.000.000.000.000.00p0.000.00
DPS Growth%0.000.000.000.000.000.00%0.000.00
Dividend Yield%0.000.000.000.000.000.00%0.000.00
Dividend Coverx0.000.000.000.000.000.00x0.000.00
Shareholder Funds€m42.8655.9414.90(1.19)33.0421.89$m0.000.00
Net Borrowings€m(31.54)(17.43)(15.20)(0.17)(8.27)(20.51)$m0.000.00
Net Assets€m42.8655.9414.90(1.19)33.0421.89$m0.000.00
Net Assets P/S0.000.000.000.000.000.00$0.000.00
Financials
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-111.2%-152.0%
ROCE171.8%
Director Deals
Traded Action Notifier Price Amount Value
09-Oct-17PlacingJames Culverwell20.00p221,592,344,318.40
09-Oct-17PlacingRory Nealon20.00p221,592,344,318.40
09-Oct-17PlacingJoe Wiley20.00p221,592,344,318.40
09-Oct-17PlacingHarry Stratford20.00p150,000,330,000
09-Oct-17PlacingMarkus Ziener20.00p132,955,326,591
09-Oct-17PlacingJoe Wiley20.00p 221,592£44,318.40
09-Oct-17PlacingRory Nealon20.00p 221,592£44,318.40
09-Oct-17PlacingJames Culverwell20.00p 221,592£44,318.40
09-Oct-17PlacingHarry Stratford20.00p 150,000£30,000
09-Oct-17PlacingMarkus Ziener20.00p 132,955£26,591
First PagePrev PageNext Page  Rows per page
Shareholders
275m    Major: 53%    Director: 12%
Notifier Holding Value
Joe Wiley20,994,487,725,084.32
Rory Nealon9,664,623,254,468.02
Ray Stafford2,296,369Ī,068.69
Markus Ziener232,955,237.56
James Culverwell221,592,762.64
  Rows per page
Gearing & Cover
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change

No data

  Rows per page
Notes

This functionality requires you to login

Click here to login
Or register for a new account